Reported research findings
- No established human clinical trials define efficacy or safety for this blend; the evidence base is real-world research use and preclinical work, not documented human trials.
HEALING & TISSUE REPAIR
BPC-157/TB-500
A widely used healing and recovery blend combining BPC-157 with the Thymosin Beta-4 fragment TB-500.
This blend combines BPC-157 (“Body Protection Compound”) with TB-500 (a Thymosin Beta-4 fragment) for systemic and localized repair. It is among the most widely used recovery compounds in the research community, with an extensive real-world track record—though formal human clinical trials are essentially absent.
Why BLP features BPC-157/TB-500
Included honestly: it has one of the strongest real-world use histories of any recovery compound, which we show transparently through its high Established Use score. At the same time, formal human clinical evidence is essentially absent—so its research maturity is Experimental. Both facts are shown side by side rather than blending popularity into evidence.
Mechanism
BPC-157 is described as up-regulating growth factors, protecting the GI tract, and speeding angiogenesis.
TB-500 is an actin-binding peptide described as promoting cell migration, flexibility, and systemic healing.
WHAT THE RESEARCH MEASURED
Research findings
Findings describe study outcomes, not expected personal results.
Preclinical findings
- Research-community use reports faster tendon and ligament recovery.
- Reported reduced joint pain and inflammation, and noticeable gut comfort and repair.
- Reported improved flexibility, less scar tissue, and faster overall recovery from training or injury.
- Both peptides are widely reported as very well tolerated in research use.
Regulatory status
BPC-157 and TB-500 are investigational with no established human clinical trials. Sold and offered strictly for laboratory and research use.